Invention Grant
- Patent Title: Method for predicting responsiveness to a treatment with an EGFR inhibitor
-
Application No.: US14360311Application Date: 2012-11-23
-
Publication No.: US10400284B2Publication Date: 2019-09-03
- Inventor: Thomas Rio Frio , Pierre Laurent-Puig , Sandrine Imbeaud
- Applicant: Integragen , Institut National de la Sante et de la Recherche Medicale (INSERM) , Centre National de la Recherche Scientifique (CNRS) , Assistance Publique—Hopitaux de Paris , Universite Paris Descartes
- Applicant Address: FR Evry FR Paris FR Paris FR Paris FR Paris
- Assignee: INTEGRAGEN,INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM),CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS),ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS,UNIVERSITE PARIS DESCARTES
- Current Assignee: INTEGRAGEN,INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM),CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS),ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS,UNIVERSITE PARIS DESCARTES
- Current Assignee Address: FR Evry FR Paris FR Paris FR Paris FR Paris
- Agency: Buchanan Ingersoll & Rooney PC
- Priority: EP11306568 20111125; EP12306042 20120831
- International Application: PCT/EP2012/073535 WO 20121123
- International Announcement: WO2013/076282 WO 20130530
- Main IPC: G01N33/48
- IPC: G01N33/48 ; C12Q1/6886
Abstract:
The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level hsa-miR-31-3p miRNA in a sample of said patient. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.
Public/Granted literature
- US20140370029A1 METHOD FOR PREDICTING RESPONSIVENESS TO A TREATMENT WITH AN EGFR INHIBITOR Public/Granted day:2014-12-18
Information query
